TD Plans 100 New U.S. Branches; Expansion Signals AML Progress but Hinges on Regulatory Approval

What happened

TD announced plans to open 100 new U.S. branches by end-2028, subject to regulatory approval, resuming an expansion strategy paused during AML remediation. The plan signals management's confidence that remediation progress will eventually lift the OCC asset limitation and permissioning regime. However, the branch addition is conditional on OCC acceptance of improved controls, which remains uncertain and is not guaranteed. The master report's WAIT rating is based on needing observable validation milestones in 2026; this news provides forward-looking intent but does not confirm near-term relief. Given the bank's current U.S. loan and deposit contraction, branch expansion would pivot from balance-sheet restructuring back to growth, contingent on regulator green light.

Implication

Investors should treat the branch announcement as a leading indicator rather than a catalyst. If the OCC approves the expansion, it would validate that remediation milestones are being met and could accelerate the bull case toward $145. However, the plan does not change the core near-term drivers: remediation cost run-rate, internal audit validation disclosures, and the US$434B asset cap. The stock's current valuation already embeds some optimism at 20.3x P/E, so the branch plan alone does not justify a rating change. We would need explicit regulatory acceptance or lower entry price to shift from WAIT. In the meantime, monitor quarterly remediation costs and any updates on validation progress, as those remain the primary swing factors.

Thesis delta

The branch plan does not alter the core investment thesis that TD's equity value hinges on AML validation and regulatory relief. However, it signals management's readiness to deploy capital into U.S. retail once constraints ease, which could add upside optionality to the bull case. Until approval is concrete, we maintain the WAIT rating and do not adjust probability weights.